Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec 21:5:18632.
doi: 10.1038/srep18632.

Systemic treatment of patients with metachronous peritoneal carcinomatosis of colorectal origin

T R van Oudheusden  1   2 , L G Razenberg  2   3 , Y R van Gestel  2 , G J Creemers  3 , V E Lemmens  2   4 , I H de Hingh  1
Affiliations

Systemic treatment of patients with metachronous peritoneal carcinomatosis of colorectal origin

T R van Oudheusden et al. Sci Rep. .

Abstract

Combining chemotherapy and targeted therapies has resulted in an enhanced survival in metastatic colorectal cancer (mCRC) patients. However, the result of this palliative treatment in patients with metachronous peritoneal carcinomatosis (PC) remains unknown. The current population-based study aims to investigate the use and effect of palliative systemic treatment in patients with metachronous PC of colorectal origin. Data on metachronous PC were collected between 2010 and 2011 for all patients who were diagnosed with M0 colorectal cancer between 2003 and 2008 in the Dutch Eindhoven Cancer Registry. Patient demographics and detailed data on chemotherapeutic treatment were collected and compared. Ninety-two patients with metachronous PC received chemotherapy in a palliative setting compared to 94 patients without treatment. In 36 patients, Bevacizumab was added to the treatment (39%). Overall survival was 3.4, 13, and 20.3 months in the no treatment, systemic treatment and systemic treatment + Bevacizumab respectively (P < 0.001). Male gender was a positive predictor and right sided primary tumor location a negative predictor of receiving bevacizumab. Approximately 40% of patients with metachronous PC received bevacizumab in addition to chemotherapy. Treatment with systemic chemotherapy in combination with bevacizumab may increase survival in a patients with metachronous colorectal PC.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Study population.
Figure 2
Figure 2. Kaplan Meier of survival of patients without systemic treatment (blue), with systemic treatment (red) or systemic treatment and bevacizumab (green).
See this image and copyright information in PMC

References

    1. Sadeghi B. et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 88, 358–363 (2000). - PubMed
    1. Elias D., Quenet F. & Goere D. Current status and future directions in the treatment of peritoneal dissemination from colorectal carcinoma. Surg Oncol Clin N Am 21, 611–623 (2012). - PubMed
    1. Sugarbaker P. H. & Ryan D. P. Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? Lancet Oncol 13, e362–369 (2012). - PubMed
    1. Goere D. et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann surg 257, 1065–1071 (2013). - PubMed
    1. Klaver Y. L. et al. Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy. Ann Surg Oncol 22, 2250–2256 (2011). - PubMed

Publication types